Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan ...
Interview study shows injectable on-demand treatments for hereditary angioedema may delay care and negatively impact quality of life, highlighting demand for oral options.
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best small cap stocks to buy with huge upside potential. H.C.
Dr Sood explains how the face can swell because of angioedema, a condition that can be both allergic and non-allergic.
The FDA has approved an oral pellet formulation of Orladeyo® to prevent attacks of hereditary angioedema in pediatric patients.
In this video, Jonathan A. Bernstein, MD, discusses his American College of Allergy, Asthma & Immunology Annual Scientific ...
GENESIS Pharma to distribute and commercialize Otsuka Pharmaceutical’s donidalorsen for hereditary angioedema in Central and Eastern Europe: Athens, Greece Tuesday, December 16, ...
Donidalorsen was discovered and developed by Ionis Pharmaceuticals, Inc. (Ionis). In December 2023, Otsuka acquired exclusive rights to commercialize donidalorsen in Europe through a licensing ...
Diagnosed with severe CSU and angioedema in 2018, Jessica Tagg struggled for months with excruciating hives and painful ...
The FDA has approved berotralstat oral pellets for prophylactic use in patients aged 2 to than 12 years with hereditary ...
The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results